Laboratory Corporation (NYSE: LH) is launching a screening test for ovarian cancer that targets women who are at high risk of developing the disease.

Called OvaSure, the test uses six biomarkers and research from Yale University to assess results.

According to LabCorp, the test can “discriminate: between disease-free women and ovarian cancer patients

"LabCorp is pleased to offer for high-risk women the OvaSure test to enhance the potential of detecting and treating ovarian cancer in its early or localized stage when the likelihood of survival is greatest," said Myla Lai-Goldman, chief medical officer at LabCorp.

In 2008, more than 21,000 women are expected to be diagnosed with ovarian cancer. More than 15,000 women are expected to die of the disease.